|
Switzerland
(State or other jurisdiction of
incorporation or organization) |
| |
2834
(Primary Standard Industrial
Classification Code Number) |
| |
Not Applicable
(I.R.S. Employer
Identification Number) |
|
|
Joshua A. Kaufman
Marc Recht David C. Boles Cooley LLP 55 Hudson Yards New York, New York 10001 +1 212 479 6000 |
| |
Frank Gerhard
Homburger AG Prime Tower Hardstrasse 201 CH-8005 Zürich, Switzerland +41 43 222 10 00 |
|
| | |
Page
|
| |||
| | | | ii | | | |
| | | | iii | | | |
| | | | 1 | | | |
| | | | 7 | | | |
| | | | 9 | | | |
| | | | 11 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 18 | | | |
| | | | 24 | | | |
| | | | 35 | | | |
| | | | 37 | | | |
| | | | 37 | | | |
| | | | 37 | | | |
| | | | 37 | | | |
| | | | 39 | | | |
| | | | 40 | | |
CHF in thousands
|
| |
As of
June 30, 2022 Actual |
| |
Adjusted as of
June 30, 2022 Actual |
| ||||||
| | |
(unaudited)
|
| |
(unaudited)
|
| ||||||
Cash and cash equivalents
|
| | | | 8,813 | | | | | | 12,946 | | |
Shareholders’ equity | | | | | | | | | | | | | |
Share capital
|
| | |
|
65,273
|
| | | |
|
653
|
| |
Share premium
|
| | |
|
283,716
|
| | | |
|
278,475
|
| |
Other Equity paid-in capital
|
| | |
|
—
|
| | | |
|
64,620
|
| |
Treasury shares reserve
|
| | |
|
(27,670)
|
| | | |
|
(16,336)
|
| |
Other reserves
|
| | |
|
27,646
|
| | | |
|
25,687
|
| |
Accumulated deficit
|
| | |
|
(342,103)
|
| | | |
|
(342,103)
|
| |
Total shareholders’ equity, net
|
| | |
|
6,862
|
| | | |
|
10,996
|
| |
Total capitalization
|
| | | | 6,862 | | | | | | 10,996 | | |
| | |
Shares
Beneficially Owned Prior to Offering(1) |
| |
Maximum
Number of Shares to be Sold Pursuant to this Prospectus |
| |
Shares Owned
Immediately After Sale of Maximum Number of Shares in this Offering(2) |
| |||||||||||||||||||||
Name of Selling shareholder
|
| |
Number
|
| |
Percentage
|
| |
Number
|
| |
Percentage
|
| ||||||||||||||||||
Armistice Capital Master Fund Ltd.(3)
|
| | | | 34,730,772 | | | | | | 41.37% | | | | | | 25,500,000 | | | | | | — | | | | | | — | | |
Number of shares
|
| |
Number of
registered shareholders on August 8, 2022 |
|
1 to 100
|
| |
233
|
|
101 to 1,000
|
| |
858
|
|
1,001 to 10,000
|
| |
1,036
|
|
10,001 to 100,000
|
| |
233
|
|
100,001 to 1,000,000
|
| |
10
|
|
1,000,001 to 10,000,000
|
| |
5
|
|
Above 10,000,000
|
| |
1
|
|
Shareholder structure according to category of investors (weighted by number of shares)
|
| | | | | | |
Private persons
|
| | | | 18.63% | | |
Institutional shareholders
|
| | | | 35.15% | | |
Holders of ADSs listed on Nasdaq not registered in the share register
|
| | | | 26.59% | | |
Non identified
|
| | | | 19.63% | | |
Shareholder structure by country (weighted by number of shares)
|
| | | | | | |
United States
|
| | | | 7.01% | | |
Switzerland
|
| | | | 45.41% | | |
Holders of ADSs listed on Nasdaq not registered in the share register
|
| | | | 26.59% | | |
Others
|
| | | | 1.36% | | |
Non identified
|
| | | | 19.63% | | |
Nominal share capital
|
| | | | | | | | | | | | |
December 31, 2019
|
| | | | CHF | | | | | | 32,848,635 | | |
December 31, 2020
|
| | | | CHF | | | | | | 32,848,635 | | |
December 31, 2021
|
| | | | CHF | | | | | | 49,272,952 | | |
June 30, 2022
|
| | | | CHF | | | | | | 65,272,952 | | |
August 8, 2022
|
| | | | CHF | | | | | | 652,730 | | |
Conditional share capital
|
| | | | | | | | | | | | |
December 31, 2019
|
| | | | CHF | | | | | | 16,424,317 | | |
December 31, 2020
|
| | | | CHF | | | | | | 16,424,317 | | |
December 31, 2021
|
| | | | CHF | | | | | | 24,636,476 | | |
June 30, 2022
|
| | | | CHF | | | | | | 32,636,476 | | |
August 8, 2022
|
| | | | CHF | | | | | | 326,365 | | |
Authorized share capital
|
| | | | | | | | | | | | |
December 31, 2019
|
| | | | CHF | | | | | | 16,424,317 | | |
December 31, 2020
|
| | | | CHF | | | | | | 16,424,317 | | |
December 31, 2021
|
| | | | CHF | | | | | | 24,636,476 | | |
June 30, 2022
|
| | | | CHF | | | | | | 32,636,476 | | |
August 8, 2022
|
| | | | CHF | | | | | | 326,365 | | |
|
Service
|
| |
Fee
|
|
|
•
Issuance of ADSs (e.g., an issuance of ADS upon a deposit of shares, upon a change in the ADS(s)-to- shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of shares
|
| | Up to U.S. 5¢ per ADS issued | |
|
Service
|
| |
Fee
|
|
|
•
Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the ADS(s)-to-shares ratio, or for any other reason)
|
| | Up to U.S. 5¢ per ADS cancelled | |
|
•
Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)
|
| | Up to U.S. 5¢ per ADS held | |
|
•
Distribution of ADSs pursuant to (i) stock dividends or other free stock distributions, or (i) exercise of rights to purchase additional ADSs
|
| | Up to U.S. 5¢ per ADS held | |
|
•
Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a spin-off)
|
| | Up to U.S. 5¢ per ADS held | |
|
•
ADS Services
|
| | Up to U.S. 5¢ per ADS held on the applicable record date(s) established by the depositary | |
|
•
Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and vice versa, or for any other reason)
|
| | Up to U.S. 5¢ per ADS (or fraction thereof) transferred | |
|
•
Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely transferable ADSs, and vice versa).
|
| | Up to U.S. 5¢ per ADS (or fraction thereof) converted | |
|
SEC registration fee
|
| | | $ | 3,238.48 | | |
|
Printing
|
| | | $ | 20,000.00 | | |
|
Legal fees and expenses
|
| | | $ | 100,000.00 | | |
|
Accounting fees and expenses
|
| | | $ | — | | |
|
Miscellaneous fees
|
| | | $ | 10,000.00 | | |
|
Total
|
| | | $ | 133,238.48 | | |
|
Exhibit
|
| |
Description
|
|
| | | | the year ended December 31, 2021) | |
| 10.11* | | | | |
| 10.12* | | | Amendment No. 1 to Securities Purchase Agreement, dated July 22, 2022 between the Registrant and Armistice Capital Master Fund Ltd. (incorporated by reference to Exhibit 10.2 of Form 6-K filed on July 26, 2022) | |
| 10.13* | | | Amendment No.3 to License Agreement between Indivior UK Limited and the Registrant, effective on August 1, 2022 (incorporated by reference to Exhibit 4.9 of the Annual Report on Form 20-F for the year ended December 31, 2021) | |
| 21.1* | | | | |
| 23.2* | | | | |
| 23.3** | | | | |
| 23.4** | | | | |
| 24.1** | | | | |
| 107** | | | |
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Tim Dyer
Tim Dyer
|
| |
Chief Executive Officer
(Principal Executive Officer) and Director |
| |
August 19, 2022
|
|
|
/s/ Lénaic Teyssédou
Lénaic Teyssédou
|
| |
Head of Finance
(Principal Financial and Accounting Officer) |
| |
August 19, 2022
|
|
|
/s/ Vincent Lawton
Vincent Lawton
|
| |
Director
|
| |
August 19, 2022
|
|
|
/s/ Ray Hill
Ray Hill
|
| |
Director
|
| |
August 19, 2022
|
|
|
/s/ Isaac Manke
Isaac Manke
|
| |
Director
|
| |
August 19, 2022
|
|
|
/s/ Roger Mills
Roger Mills
|
| |
Director
|
| |
August 19, 2022
|
|
|
/s/ Jake Nunn
Jake Nunn
|
| |
Director
|
| |
August 19, 2022
|
|
Exhibit 3.1
Articles of Association
of
Addex Therapeutics Ltd
I. | Corporate Name, Registered Office, Duration, Purpose |
Article 1
Corporate Name, Registered Office, Duration
Under the name Addex Therapeutics Ltd (Addex Therapeutics SA) (the "Company") exists a corporation which is subject to these Articles of Association and the provisions of Chapter 26 of the Swiss Code of Obligations (CO). The registered office of the Company is in Plan-les-Ouates, canton of Geneva. The duration of the Company shall be unlimited.
Article 2
Purpose
The purpose of the Company is to acquire, to hold, to administer continuously, to sell and to finance participations in companies of all kinds in Switzerland and abroad, to the exclusion of real estate participations, except where permitted under Swiss law.
The Company may open branch offices and subsidiaries and agencies in Switzerland and abroad. It may grant guarantees or other security in relation to liabilities of affiliated companies. In addition, the Company may engage in any other commercial, financial and other activities which may promote or relate to the purpose of the Company.
The Company may acquire, manage, exploit and sell in Switzerland and abroad intellectual property rights and, where permitted under Swiss law, real estate.
II. | Share Capital, Bons de Jouissance, Shares Certificates, Shares Register, Nominees |
Article 3
Share Capital
The share capital of the Company is CHF 652'729.52.- It is divided into 65'272’952 registered shares with a nominal value of CHF 0.01 each.
All shares are fully paid-in.
The Meeting of Shareholders may at any time convert registered shares into bearer shares or bearer shares into registered shares and, as the case may be, non-voting shares into shares, by amending these Articles of Association.
Article 3a
Bons de jouissance
The Company has issued 1,700 (one thousand seven hundred) registered bons de jouissance (profit sharing certificates/Genussscheine) to be granted to employees and/or directors of the Company or a group company according to respective regulations of the Board of Directors.
The bons de jouissance are uncertificated.
The bons de jouissance are transmissible only with the prior consent of the Board of Directors.
The bons de jouissance do not form part of the share capital and do not have a nominal value. They do not grant any right to vote nor the right to attend Meetings of Shareholders. Each bon de jouissance grants (i) a right to subscribe for 1,000 shares and (ii) a right to liquidation proceeds of the Company calculated in accordance with Article 34 of the Articles of Association.
The Company shall maintain a register of holders of bons de jouissance listing the surname and first name (in the case of legal entities, the company name), address and nationality (in the case of legal entities, the registered office) of the holders of bons de jouissance.
The provisions regarding the share register (Article 5 of the Articles of Association) shall apply mutatis mutandis to the register of holders of bons de jouissance.
The Board of Directors may at any time hold, acquire or alienate bons de jouissance for the account of the Company. The Company can at any time cancel bons de jouissance.
Article 3b
Authorized Share Capital
The Board of Directors shall be authorized, at any time until 9 may 2024 to increase the share capital in an amount of CHF 326'364.76 through the issuance of 32'636'476 fully paid registered shares with a nominal value of CHF 0.01 each. An increase in partial amounts shall be permitted. The Board of Directors shall determine the issue price, the type of payment, the date of issue of new shares, the conditions for the exercise of pre-emptive rights and the beginning date for dividend entitlement. In this regard, the Board of Directors may issue new shares by means of a firm underwriting through a banking institution, a syndicate or another third party with a subsequent offer of these shares to the current shareholders (unless the pre-emptive rights of current shareholders are excluded). The Board of Directors may permit pre-emptive rights that have not been exercised to expire or it may place these rights and/or shares as to which pre-emptive rights have been granted but not exercised, at market conditions or use them for other purposes in the interest of the Company.
The subscription and acquisition of the new shares, as well as each subsequent transfer of the shares, shall be subject to the restrictions of Article 5 of the Articles of Association.
The Board of Directors is authorized to restrict or exclude the pre-emptive rights of shareholders and allocate such rights to third parties if the shares are to be used (1) for the acquisition of enterprises, parts of an enterprise, or participations, or for new investments, or, in case of a share placement, for the financing or refinancing of such transactions; or (2) for the purpose of the participation of strategic partners (including in the event of a public tender offer) or for the purpose of an expansion of the shareholder constituency in certain investor markets or (3) for the granting of an over-allotment option (Greenshoe) of up to 20 percent to the banks involved in connection with a placement of shares, or (4) for raising capital in a fast and flexible manner, which would not be achieved without the exclusion of the statutory pre-emptive rights of the existing shareholders.
Article 3c
Conditional Share Capital
A) | The share capital of the Company may be increased by a maximum aggregate amount of CHF 187'695.78 through the issuance of a maximum of 18'769'578 registered shares, which shall be fully paid-in, with a par value of CHF 0.01 per share by the exercise of option rights or subscription rights attached to bons de jouissance which the employees, directors and/or consultants of the Company or a group company are granted according to respective regulations of the Board of Directors. The pre-emptive rights of the shareholders are excluded. The acquisition of registered shares through the exercise of option rights or subscription rights granted to the holders of bons de jouissance and the subsequent transfer of the registered shares shall be subject to the transfer restrictions pro-vided in Article 5 of the Articles of Association. |
B) | The share capital of the Company may be increased by a maximum aggregate amount of CHF 138'668.98 through the issuance of a maximum 13'866’898 registered shares, which shall be fully paid-in, with a par value of CHF 0.01 per share by the exercise of option and/or conversion rights which are granted to shareholders of the company and/or in connection with the issue of bonds, similar obligations or other financial instruments by the Company or another group company. In the case of such grants of option and/or conversion rights, the advanced subscription right of shareholders is excluded. The holders of option and/or conversion rights are entitled to receive the new shares. The Board of Directors shall determine the terms of the option and/or conversion rights. The acquisition of registered shares through the exercise of option or conversion rights and the subsequent transfer of the registered shares shall be subject to the transfer restrictions provided in Article 5 of the Articles of Association. |
The Board of Directors shall be authorized to restrict or exclude the advanced subscription rights of shareholders (1) if the debt or other financial instruments and/or conversion rights or warrants are issued for the purpose of financing or refinancing of the acquisition of enterprises, parts of an enterprise, or participations or new investments or (2) if such debt or other financial instruments and/or conversion rights or warrants are issued on the national or international capital markets and for the purpose of a firm underwriting by a banking institution or a consortium of banks with subsequent offering to the public or (3) if such debt or other financial instruments and/or conversion rights or warrants are issued for raising capital in a fast and flexible manner, which would not be achieved without the exclusion of the advanced subscription rights of the existing shareholders.
If the advance subscription rights are excluded by the Board of Directors, the following hall apply: the issuance of convertible bonds or warrants or other financial market instruments shall be made at the prevailing market conditions (including dilution protection provisions in accordance with market practice) and the new shares shall be issued pursuant to the relevant conversion or exercise rights in connection with bond or warrant issue conditions. Conversion rights may be exercised during a maximum 10-year period, and warrants may be exercised during a maximum 7-year period, in each case from the date of the respective issuance."
Article 4
Abolished Printing of Share Certificates
The shareholder may at any time request the Company to issue a confirmation of the number of registered shares held by such shareholder. The shareholder is not entitled, however, to request the printing or delivery of share certificates for registered shares. The Company may, on the other hand, at any time print and deliver share certificates for registered shares, and may, with the consent of the shareholder, cancel share certificates that are delivered to it, without replacement.
Uncertificated registered shares, including any uncertificated rights arising thereunder, may be transferred only by way of assignment. In order to be valid, such assignment requires notification to the Company.
If a bank administers uncertificated registered shares on a shareholders' behalf, such shares and the uncertificated rights arising thereunder may only be transferred with the bank's cooperation. Furthermore, they can only be pledged in favor of such bank, in which case no notification to the Company is required.
Article 5
Share Register, Nominees
The Company shall maintain a share register listing the surname and first name (in the case of legal entities, the company name), address and nationality (in the case of legal entities, the registered office) of the owners and usufructuaries of the registered shares. If a registered shareholder changes his address, the new address must be communicated to the Company. As long as this has not been done, all notices by letter will be sent validly to the address entered in the share register.
Acquirers of registered shares shall upon application be registered as shareholders with the right to vote, provided that they expressly declare that they acquired the registered shares in their own name and for their own account.
The Board of Directors may register nominees with the right to vote in the share register to the extent of up to 5% of the registered share capital as set forth in the commercial register. Registered shares held by a nominee that exceed this limit may be registered in the share register with the right to vote if the nominee discloses the names, addresses and the number of shares of the persons for whose account it holds 1% or more of the registered share capital as set forth in the commercial register. Nominees within the meaning of this provision are persons who do not explicitly declare in the request for registration to hold the shares for their own account and with whom the Board of Directors has entered into a corresponding agreement.
Corporate bodies and partnerships or other groups of persons or joint owners who are interrelated to one another through capital ownership, voting rights, uniform management or otherwise as well as individuals or corporate bodies and partnerships who act in concert to circumvent the regulations concerning the nominees (especially as syndicates), shall be treated as one single nominee within the meaning of the preceding paragraph.
After hearing the registered shareholder or nominee, the Board of Directors may cancel, with retroactive effect as of the date of registration if appropriate, the registration of shareholders if the registration was effected based on false information or in case of breach of the agreement between the nominee and the Board of Directors. The respective shareholder or nominee shall be informed immediately of the cancellation of the registration.
The Board of Directors shall specify the details and give the necessary orders concerning the adherence to the preceding regulations. In particular cases it may allow exemptions from the regulation concerning nominees. It may delegate its duties.
The limitation for registration in the share register provided for in this Article shall also apply to shares acquired or subscribed by the exercise of subscription, option or conversion rights.
Article 6
Exercise of Shareholders' Rights
Shares are not divisible. The Company shall only accept one representative per share.
The voting rights and other rights associated with a registered share may only be exercised by a shareholder, usufructuary or nominee registered in the share register with the right to vote, or by persons who are entitled by law to the voting right of a share, subject to Article 13, which regulates the representation of the shareholders.
III. | Corporate Bodies |
Article 7
Corporate Bodies
The corporate bodies of the Company are:
a) | The Meeting of Shareholders; |
b) | The Board of Directors; |
c) | The (statutory) Auditors. |
A. | The Meeting of Shareholders |
Article 8
Powers of the Shareholders Meeting
The Meeting of Shareholders is the supreme body of the Company. The following non-delegable powers are vested in the Meeting of Shareholders:
1. | to adopt and amend the Articles of Association; |
2. | to elect and remove the members of the Board of Directors, the Chairman of the Board of Directors, the members of the Compensation Committee, the Auditors and the Independent Voting Rights Representative; |
3. | to approve the annual report and the consolidated financial statements; |
4. | to approve the annual financial statements and to determine the allocation of profits as shown on the balance sheet, in particular with regard to dividends; |
5. | to approve the compensation of the Board of Directors and the Executive Management in accordance with Article 27 of these Articles of Association; |
6. | to grant discharge to the members of the Board of Directors and the persons entrusted with management; |
7. | to pass resolutions concerning all matters reserved to the authority of the Meeting of Shareholders by law or under the Articles of Association. |
Article 9
Ordinary and Extraordinary Meeting of Shareholders
The Ordinary Meeting of Shareholders shall be held each year within six months after the close of the business year.
Extraordinary Meetings of Shareholders shall be held when deemed necessary by the Board of Directors or the Auditors or demanded by a resolution of the shareholders in a Meeting of Shareholders. Furthermore, an Extraordinary Meeting of Shareholders shall be convened if this is requested by one or more shareholder(s) who represent an aggregate amount of at least 10 percent of the share capital and who submit in writing a petition specifying the items for the agenda and the proposals, and, in case of elections, the name of the proposed candidates.
Article 10
Convocation
The Meeting of Shareholders shall be called by the Board of Directors or, if necessary, the Auditors, no later than 20 days prior to the meeting date. The liquidators shall also be entitled to call a Meeting of Shareholders.
Notice of the meeting shall be given by way of an announcement appearing once in the official publication organ of the Company. Holders of registered shares may also be informed by ordinary mail.
The annual business report, the Compensation Report and the Auditor’s report and, if any, the Group Auditor's report must be available for examination by the Shareholders at the registered office of the Company at least 20 days prior to the date of the Ordinary Meeting of Shareholders. Such reference shall be included in the invitation to the Ordinary Meeting of Shareholders.
The notice of a meeting shall state the items on the agenda and the proposals of the Board of Directors and, if applicable, of the shareholders who demanded that a Meeting of Shareholders be held or that an item be included in the agenda and, in case of elections, the names of the nominated candidates.
Article 11
Agenda
One or more shareholders whose combined shareholdings represent an aggregate nominal value of at least CHF 1,000,000 or at least 10 percent of the share capital may demand that an item be included on the agenda of a Meeting of Shareholders. Such a request must be made in writing to the Board of Directors at the latest 60 days before the Meeting and shall specify the agenda items and the proposals made.
No resolution may be passed on agenda items for which no proper notice was given; this prohibition does not apply, however, to proposals made during a Meeting of Shareholders to call an Extraordinary Meeting of Shareholders or to initiate a special audit.
No prior notice is required for proposals concerning items included on the agenda and for debates as to which no vote is taken.
Article 12
Chairman, Vote Counters, Minutes
The Meeting of Shareholders shall be chaired by the Chairman of the Board. In his absence, the Vice-Chairman or any other member of the Board designated by the Board shall take the chair.
The Chairman of the Meeting shall designate the Secretary and the vote counters, who need not be shareholders. The minutes shall be signed by the Chairman of the Meeting and the Secretary.
Article 13
Voting Rights, Proxies, Independent Voting Rights Representative
Each share recorded as share with voting rights in the share register confers one vote on its registered holder.
The Board of Directors shall issue procedural rules regarding participation in and representation at the Meeting of Shareholders. Every shareholder may be represented at the Meeting of Shareholders by the Independent Voting Rights Representative or any person who is authorized by a written proxy. A proxy need not be a shareholder.
The General Meeting of Shareholders shall elect the Independent Voting Rights Representative for a term of office extending until completion of the next Annual General Meeting of Shareholders. Re-election is permitted.
If the Company does not have an Independent Voting Rights Representative, the Board of Directors shall appoint the Independent Voting Rights Representative for the next General Meeting of Shareholders.
Article 14
Resolutions, Elections
Unless otherwise required by law or these Articles of Association, the Meeting of Shareholders shall pass resolutions and decide elections upon an absolute majority of votes represented. In case of a tie, the Chairman of the Meeting shall have a casting vote.
Resolutions and elections shall be decided by a show of hands, unless a vote by written ballot or in electronic manner is resolved by the Meeting of Shareholders or ordered by the Chairman of the Meeting. The Chairman of the Meeting may at any time order to repeat an election or resolution taken on a show of hands with a written or electronic ballot, if he doubts the results of the vote. In this case, the preceding election or resolution taken on a show of hands is deemed not to have occurred.
If the first ballot fails to result in an election and more than one candidate is standing for election, the Chairman of the Meeting shall order a second ballot in which a relative majority shall be decisive.
B. | Board of Directors |
Article 15
Number of Directors
The Board of Directors shall consist of a minimum of 1 member and a maximum of 11 members.
Article 16
Election, Term of Office
The members of the Board of Directors and the Chairman of the Board of Directors are elected individually by the General Meeting of Shareholders for a term of office extending until completion of the next Annual General Meeting of Shareholders.
Members whose term of office has expired are immediately eligible for re-election.
Should the position of Chairman of the Board of Directors become vacant, the Board of Directors shall appoint a new Chairman from among its members for a term of office extending until completion of the next Ordinary General Meeting of Shareholders.
Article 17
Organization of the Board of Directors
Except for the election of the Chairman of the Board of Directors and the members of the Compensation Committee by the General Meeting of Shareholders, the Board of Directors shall determinate its own organisation. It may elect from its members one or, if necessary, several Vice-Chairmen. The Board of Directors shall further appoint a Secretary, who need not be a member of the Board of Directors.
The Board of Directors may appoint from amongst its members standing or ad hoc committees entrusted with the preparation and execution of its decisions or the supervision of specific parts of the business. The Board of Directors shall ensure that it is kept properly informed.
Subject to mandatory law and the provisions of these Articles of Association, the Board of Directors determines its own internal organization and the modalities for the passing of resolutions in Organizational Rules.
Article 18
Convening of Meetings, Resolutions, Minutes
The Chairman, in his absence the Vice-Chairman or any other member of the Board of Directors shall convene meetings if and when the need arises or whenever a member requests a meeting in writing setting forth the reasons for the meeting. A meeting may also be held by telephone or video conference.
The adoption of resolutions of the Board of Directors requires a majority of the votes cast.
Resolutions may also be passed in writing (including by telefax or by electronic signature) unless a member of the Board of Directors requests oral deliberation.
Article 19
Attributions
The Board of Directors may pass resolutions concerning all matters not reserved to the authority of any other corporate body by law, these Articles of Association or regulations.
The Board of Directors has, in particular, the following non-delegable and inalienable duties:
1. | the ultimate direction of the Company and the issuance of the necessary instructions; |
2. | the determination of the organization of the Company; |
3. | the structuring of the accounting system, financial control and financial planning; |
4. | the appointment and removal of the persons entrusted with management and representation of the Company, as well as the determination of their signatory power; |
5. | the ultimate supervision of the persons entrusted with management of the Company, specifically in view of their compliance with the law, these Articles of Association, the regulations and directives; |
6. | the preparation of the business report and the Compensation report, preparation of the Meetings of Shareholders and the implementation of the resolutions adopted by the Meeting of Shareholders; |
7. | the passing of resolutions regarding the subsequent payment of capital with respect to non fully paid-in shares; |
8. | the passing of resolutions concerning an increase in share capital to the extent that such power is vested in the Board of Directors (art. 651 para. 4 CO) and of resolutions concerning the confirmation of capital increases and corresponding amendments to the Articles of Association, as well as making the required report on the capital increase; |
9. | the non-delegable and inalienable duties and powers of the board of directors pursuant to the Swiss Merger Act and any other law; |
10. | the notification of the judge if liabilities exceed assets. |
In addition, the Board of Directors may, within the limits of the law and by virtue of the Organizational Rules, delegate in whole or in part, its powers, as well as management and the representation of the Company to one or several members of the Board of Directors or to third parties.
C. | Compensation Committee |
Article 20
Number of members, election, term of office
The Compensation Committee shall comprise 1 to 3 members of the Board of Directors. If the Board of Directors consists of less than 4 members, the Compensation Committee may consist of the same members as the Board of Directors.
Members of the Compensation Committee shall be elected individually by the General Meeting of Shareholders for a term of office extending until completion of the next Ordinary General Meeting of Shareholders.
The members of the Compensation Committee are immediately eligible for re-election at the end of their term of office.
Article 21
Organization of the Compensation Committee
The Compensation Committee shall determine its own organization. The Board of Directors shall elect the Chairman of the Compensation Committee.
The Board of Directors shall issue regulations establishing the organization and decision making process of the Compensation Committee.
Article 22
Powers and Duties of the Compensation Committee
The Compensation Committee shall support the Board of Directors in establishing and reviewing the compensation strategy and guidelines as well as in preparing the proposals to the General Meeting of Shareholders regarding the compensation of the Board of Directors and of the Executive Management, and may submit proposals to the Board of Directors in other compensation-related issues.
The Board of Directors shall determine in regulations for which positions of the Board of Directors and of the Executive Management the Compensation Committee shall submit proposals for the performance metrics, target values and the compensation to the Board of Directors, and for which positions it shall itself determine, in accordance with the Articles of Association and the compensation guidelines established by the Board of Directors, the performance metrics, target values and the compensation.
The Board of Directors may delegate further tasks to the Compensation Committee that shall be determined in regulations.
Article 23
Election, Term of Office
The Meeting of Shareholders shall elect the Auditors.
The term of office of the Auditors shall be one year. The term of office commences on the day of the election and expires on the day of the next Ordinary Meeting of Shareholders.
The Meeting of Shareholders may for purposes of the special reviews required in connection with capital increases (articles 652f, 653f, 653i CO) elect special auditors. If no special auditors have been elected, the regular Auditors are in charge of these tasks.
Article 24
Duty to Audit and Report
The Auditors perform their duties in accordance with the applicable provisions of the Swiss Code of Obligations.
Article 25
Special Audits, Interim Audits
The Board of Directors may at any time request the Auditors to conduct special audits, including interim audits, and to submit their reports.
IV. | Compensation of the Board of Directors and Executive Management |
Article 26
General principles of compensation
The compensation of the members of the Board of Directors consists of fixed and variable compensation elements. The total compensation shall take into consideration position and level of responsibility of the recipient.
The compensation of the members of the Executive Management consists of fixed and variable compensation elements. The fixed compensation comprises the base salary and other compensation elements. The variable compensation may comprise short-term and long term variable compensation elements. The compensation shall take into consideration position and level of responsibility of the recipient.
The short-term variable compensation elements shall be governed by performance metrics that take into account the performance of the Company, the group or parts thereof, targets in relation to the market, other companies or comparable benchmarks and/or individual targets, and achievement of which is generally measured during a one-year period.
Long-term variable compensation elements shall be governed by performance metrics that take into account strategic and/or financial objectives, achievement of which is generally measured during a perennial period, as well as retention elements.
Depending on achieved performance, the compensation may amount to a predetermined multiplier of target level.
The Board of Directors or, to the extent delegated to it, the Compensation Committee shall determine the performance metrics and target levels of the short- and long-term variable compensation elements, as well as their achievement.
The compensation may be paid in the form of cash, shares, share-based instruments or units or in the form of other types of benefits. The Board of Directors or, to the extent delegated to it, the Compensation Committee shall determine grant, vesting, exercise and forfeiture conditions. In particular, they may provide for continuation, acceleration or removal of vesting and exercise conditions, for payment or grant of compensation based upon assumed target achievement, or for forfeiture, in each case in the event of pre-determined events such as a change-of-control or termination of an employment or mandate agreement. The Company may procure the required shares through purchases in the market or by using conditional share capital.
Compensation may be paid by the Company or companies controlled by it.
Article 27
Approval of Compensation by the General Meeting of Shareholders
The General Meeting of Shareholders shall approve the proposals of the Board of Directors in relation to the maximum aggregate amounts of:
1. | the compensation of the Board of Directors for the next term of office; |
2. | the compensation of the Executive Management for the next financial year. |
The Board of Directors may submit for approval by the General Meeting of Shareholders deviating or additional proposals relating to the same or different periods.
In the event the General Meeting of Shareholders does not approve a proposal of the Board of Directors, the Board of Directors shall determine, taking into account all relevant factors, the respective (maximum) aggregate amount or (maximum) partial amounts, and submit the amount(s) so determined for approval by the same Annual General Meeting of Shareholders, an Extraordinary General Meeting of Shareholders or the next Annual General Meeting of Shareholders.
The compensation may be paid out prior to approval by the General Meeting of Shareholders subject to sub - sequent approval.
Article 28
Additional amounts in case of changes in the Executive Management
If the maximum aggregate amount of compensation already approved by the General Meeting of Shareholders is not sufficient to also cover the compensation of one or more persons who become members of the Executive Management or are being promoted within the Executive Management after the General Meeting of Shareholders has approved the compensation of the Executive Management for the relevant period then the Company or companies controlled by it shall be authorised to pay such member(s) a supplementary amount during the compensation period(s) already approved. The supplementary amount per compensation period shall in total not exceed 100% of the maximum aggregate amount of compensation of the Executive Management last approved.
V. | Agreements with members of the Board of Directors and of the Executive Management, loans |
Article 29
Agreements with members of the Board of Directors and of the Executive Management
The Company or companies controlled by it may enter into agreements for a fixed term or for an indefinite term with members of the Board of Directors with respect to their compensation. The duration and termination shall comply with the term of office and the law.
The Company or companies controlled by it may enter into employment agreements for a fixed term or for an indefinite term with members of the Executive Management. Employment agreement for a fixed term may have a maximum duration of one year; renewal is permitted. Employment agreements for an indefinite term may have a termination notice period of maximum twelve months.
The Company or companies controlled by it may enter agreements on non-compete with members of the Executive Management for the time after termination of employment. Their duration shall not exceed one year, and consideration paid for such non-compete undertaking shall not exceed the last total annual compensation of such member of the Executive Management.
Article 30
Credits
Credits may not be granted to members of the Board of Directors or the Executive Management
VI. | Mandates Outside the Group |
Article 31
No member of the Board of Directors may hold more than fourteen additional mandates of which no more than four mandates may be in companies listed on a stock exchange.No member of Executive Management may hold more than five mandates of which no more than two may be in companies listed on a stock exchange.
The following mandates shall not be subject to the above mentioned limitations:
1. | Mandates in companies that are controlled by the Company or which control the Company; |
2. | Mandates that are carried out at the request of the Company or companies controlled by it. No member of the Board of Directors or of the Executive Management shall carry out more than ten such mandates; and |
3. | Mandates in associations, non-profit organizations, foundations, trusts and employee welfare foundations, education institutions, non-profit institutions and other similar organisations. No members of the Board of Director or of the Executive Management may carry out more than twenty-five such mandates. |
Mandates shall mean mandates in the supreme governing body of a legal entity which is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control or same beneficial ownership are deemed one mandate.
VII. | Financial Year, Allocation of Profits |
Article 32
Financial Year, Annual Report
The Board of Directors determines the beginning and the end of the business year.
For each business year, the Board of Directors shall prepare an annual report consisting of the annual financial statements (including the profit and loss statements, balance sheet and notes to the financial statements), the business report and the consolidated financial statements.
Article 33
Allocation of Profits, Reserves
The profit shown on the balance sheet shall be allocated by the Meeting of Shareholders within the limits set by applicable law. The Board of Directors shall submit its proposals to the Meeting of the Shareholders.
Further reserves may be taken in addition to the reserves required by law.
Dividends that have not been claimed within five years after their due date shall pass to the Company and be allocated to the general reserves.
VIII. | Dissolution |
Article 34
Dissolution, Liquidation
The Meeting of Shareholders may at any time resolve the dissolution and liquidation of the Company in accordance with the provisions of the law and of the Articles of Association.
The liquidation shall be carried out by the Board of Directors to the extent that the Meeting of Shareholders has not entrusted the same to other persons.
The liquidation of the Company shall take place in accordance with article 742 seq. CO. The liquidators are authorized to dispose of the assets (including real estate) by way of private contract.
After all debts have been satisfied, the net proceeds shall be distributed among the shareholders and the holders of bons de jouissance in proportion to the number of shares and the number of subscription rights attached to the bons de jouissance.
IX. | Notices, Communications |
Article 35
Notices, Communications
The official publication organ of the Company shall be the Swiss Official Gazette of Commerce (Feuille Officielle Suisse du Commerce). The Board of Directors may designate other publication organs as well.
To the extent that personal notification is not mandated by law, all communications to the shareholders shall be deemed valid if published in the Swiss Official Gazette of Commerce.
In case of written communications by the Company to its shareholders, such shall be sent by ordinary mail to the last address of the shareholder entered in the share register of the Company.
X. | Contribution in Kind, Acquisition of Assets |
Article 36
Contribution in Kind
Mr. Timothy Dyer contributes to the Company, on its own behalf and on a fiduciary basis:
(i) | 3,317,492 (three-million-three-hundred-seventeen-thousand-and-four-hundred-ninety-two) fully paid-in shares of Addex Pharma SA (formerly Addex Pharmaceuticals SA) in Plan-les-Ouates (Geneva) with a nominal value of CHF 1 (one Swiss Franc) each. |
This contribution in kind is made and accepted at the price of CHF 3,317,492 (three-million-three-hundred-seventeen-thousand-four-hundred ninety-two Swiss Francs), entirely made on account of the share capital.
In consideration for this contribution in kind, the Company allots 3,317,492 (three-million-three-hundred-seventeen-thousand-four-hundred-ninety-two) fully paid-in registered shares with a nominal value of CHF 1 (one Swiss Franc) each.
(ii) | 670,000 (six-hundred-seventy-thousand) fully paid-in non-voting shares (bons de participation) with a nominal value of CHF 1 (one Swiss Franc) each, representing the entire capital of non-voting shares (capital-participation) of Addex Pharma SA (formerly Addex Pharmaceuticals SA) in Plan-les-Ouates (Geneva). |
This contribution in kind is made and accepted at the price of CHF 670,000 (six-hundred-seventy-thousand), entirely made on account of the share capital.
In consideration for this contribution in kind, the Company allots 670,000 (six-hundred-seventy-thousand) fully paid-in non-voting shares (bons de participation) with a nominal value of CHF 1 (one Swiss Franc) each.
Article 37
Acquisitions of Assets
The Company has acquired from Addex Pharma SA (formerly Addex Pharmaceuticals SA) in Plan-les-Ouates (Geneva) the entire share capital of Addex Pharmaceuticals France SAS, a company incorporated under the laws of France with registered seat in Archamps (France), that is, 37,000 (thirty-seven-thousand) shares with a nominal value of EUR 1 each (one Euro), for the total purchase price of CHF 1 (one Swiss Franc).
XI. | Miscellaneous |
Article 38
Translation of the Articles of Association
The Articles of Association are translated in English. The French text is the only official version.
Article 39
Opting-out
Growth Equity Opportunities Fund IV, LLC, c/o New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093, and New Leaf Biopharma Opportunities I, L.P., 7 Times Square, Suite 3502, New York, NY 10036, United States, in each case including their direct or indirect partners or shareholders as well as any other entity or person (whether incorporated or not) that alone or together with others controls or otherwise holds any relevant interest in them, are, when acting alone or in concert pursuant to art. 135 of the Swiss Federal Act on Financial Markets Infrastructures (FMIA) exempted from the duty pursuant to art. 135 FMIA (Opting-out within the meaning of art. 125 para. 3 FMIA). The foregoing Opting-out provision will expire on March 21, 2023 with effect for any crossing of the threshold pursuant to art. 135 FMIA which occurs thereafter.
**********
Le notaire soussigné certifie que les présents statuts, sont ceux en vigueur à l'issue de l'assemblée générale ordinaire du neuf mai deux mil vingt-deux et de la séance du conseil d'administration du quatorze juillet deux mil vingt-deux.
Genève, le 14 juillet 2022/ns
Exhibit 5.1
Confidential To: Addex Therapeutics Ltd |
Homburger AG Prime Tower Hardstrasse 201 CH-8005 Zürich
homburger.ch |
August 19, 2022 | |
Addex Therapeutics Ltd – Registration Statement on Form F-1 – Exhibit 5.1 | |
Ladies and Gentlemen:
We have acted as special Swiss counsel to Addex Therapeutics Ltd, a stock corporation incorporated under the laws of Switzerland (the Company), in connection with the filing on August 19, 2022 of a registration statement on Form F-1 (the Registration Statement) with the United States Securities and Exchange Commission (the SEC) for the purpose of registering under the United States Securities Act of 1933, as amended (the Securities Act), the offer and sale of up to an aggregate of 4,250,000 American Depositary Shares (the ADSs), representing 25,500,000 registered shares in the Company, with a nominal value of CHF 0.01 each (the Warrant Shares), consisting of (i) 2,500,000 ADSs (representing 15,000,000 Warrant Shares) issuable upon the exercise of ordinary warrants, exercisable 60 days after the date of their issuance at an exercise price of USD 1.90 per ADS, and (ii) 1,750,000 ADSs (representing 10,500,000 Warrant Shares) issuable upon the exercise of pre-funded warrants, exercisable immediately at an exercise price of USD 0.01 per ADS.
Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Documents.
I. | Basis of Opinion |
This opinion is confined to and given on the basis of the laws of Switzerland in force at the date hereof. Such laws and the interpretation thereof are subject to change. In the absence of explicit statutory law, we base our opinion solely on our independent professional judgment. This opinion is also confined to the matters stated herein and the Documents (as defined below), and is not to be read as extending, by implication or otherwise, to any agreement or document referred to in any of the Documents (including, in the case of the Registration Statement (as defined below), any document incorporated by reference therein or exhibited thereto) or any other matter.
For purposes of this opinion, we have only reviewed originals or copies of the following documents (collectively the Documents):
(i) | an electronic copy of the Registration Statement; |
(ii) | an electronic copy of articles of association (statuts) of the Company dated July 14, 2022, notarized by a licensed notary of the Canton of Geneva on July 14, 2022 (the Articles); |
(iii) | an electronic copy of an internet excerpt (extrait internet) from the Commercial Register of the Canton of Geneva dated August 19, 2022 relating to the Company (the Excerpt). |
No documents, other than the Documents, have been reviewed by us in connection with this opinion. Accordingly, we shall limit our opinion to the Documents and their legal implications under Swiss law.
In this opinion, Swiss legal concepts are expressed in English terms and not in their original language. These concepts may not be identical to the concepts described by the same English terms as they exist under the laws of other jurisdictions.
II. | Assumptions |
In rendering the opinions below, we have assumed the following:
(a) | all documents produced to us as originals are authentic and complete, and all documents produced to us as copies (including, without limitation, electronic copies) conform to the original; |
(b) | all documents produced to us as originals and the originals of all documents produced to us as copies were duly executed and certified, as applicable, by the individuals purported to have executed or certified, as the case may be, such documents, and any electronic or facsimile signatures thereon have been produced and used in accordance with applicable internal rules and/or procedures and the individual to whom any such electronic or facsimile signature belongs has consented to the use of his or her signature for each such document on which it appears; |
(c) | the Registration Statement is unchanged and correct, complete and up-to-date and in full force and effect as of the date hereof and no changes or events have occurred which should have been or should be reflected in the Registration Statement as of the date hereof; |
(d) | all signatures appearing on all original documents or copies thereof (including, without limitation, electronic copies) which we have examined are genuine and authentic; |
(e) | to the extent relevant for purposes of this opinion, any and all information contained in the Documents is, and all material statements made to us in connection with the Documents are and will be, true, complete and accurate at all relevant times; |
(f) | the Company has not entered and will not enter into any transaction which could be construed as repayment of share capital (restitution des versements) and has not undertaken and will not undertake an acquisition in kind (reprise de biens) or intended acquisition in kind (reprise de biens envisagée) without complying with the formal procedure set forth in article 628 of the Swiss Code of Obligations; |
(g) | all authorizations, approvals, consents, licenses, exemptions, other than as required by mandatory Swiss law applicable to the Company or the Articles, and other requirements for the filing of the Registration Statement or for any other activities carried on in view of, or in connection with, the performance of the obligations expressed to be undertaken by the Company in the Registration Statement have been duly obtained or fulfilled in due time and are and will remain in full force and effect, and any related conditions to which the parties thereto are subject have been satisfied; |
(h) | the Articles and the Excerpt are unchanged and correct, complete and up-to-date and in full force and effect as of the date hereof and no changes have been made which should have been or should be reflected in the Articles or the Excerpt as of the date hereof; |
(i) | the Company is, at the date hereof, not insolvent or over-indebted (in the sense of article 725 of the Swiss Code of Obligations (the CO)); |
(j) | the Company intends to produce and publish financial statements in accordance with articles 958 et seq. at least annually; and |
(k) | no laws (other than those of Switzerland) affect any of the conclusions stated in this opinion. |
III. | Opinion |
Based on the foregoing assumptions and subject to the qualifications set out below, we express the following opinion:
1. | The Warrant Shares which will be sourced from existing treasury shares have been validly issued, are fully paid as to their nominal value and are non-assessable. |
2. | The Warrant Shares which are to be newly issued, if and when (i) issued and paid for pursuant to the Articles and Swiss law and (ii) registered in the Commercial Register of the Canton of Geneva and the Company's uncertificated securities book (registre des droits-valeurs), will have been validly issued, fully paid as to their nominal value and non-assessable. |
IV. | Qualifications |
The above opinion is subject to the following qualifications:
(a) | The lawyers of our firm are members of the Zurich bar and do not hold themselves out to be experts in any laws other than the laws of Switzerland. Accordingly, we are opining herein as to Swiss law only and we express no opinion with respect to the applicability or the effect of the laws of any other jurisdiction to or on the matters covered herein. |
(b) | The exercise of voting rights and rights related thereto with respect to any Warrant Shares is only permissible after registration in the Company's share register as a shareholder with voting rights in accordance with the provisions of and subject to the limitations provided in the Articles. |
(c) | We express no opinion as to whether the Registration Statement is accurate, true, correct, complete or not misleading. In particular, and without limitation to the foregoing, we express no opinion on whether the Registration Statement provides sufficient information for investors to reach an informed assessment of the Company, any companies within the Company’s consolidation perimeter and the Warrant Shares. |
(d) | We express no opinion as regards the exclusion of shareholders’ pre-emptive subscription rights (droits de souscription préférentiels). |
(e) | We express no opinion as to tax, regulatory matters or as to any commercial, accounting, calculating, auditing or other non-legal matter. |
(f) | If used in this opinion, the term "non-assessable" means that no further contributions will have to be made by the relevant holder of the Warrant Shares. |
* * *
We have issued this opinion as of the date hereof and we assume no obligation to advise you of any changes that are made or brought to our attention hereafter.
This letter is addressed to you in connection with the Registration Statement. We consent to the filing of this letter as an exhibit to the Registration Statement. No other person may rely on this opinion for any purpose. Without our prior written consent, this opinion may not (in full or in part) be copied, furnished or quoted to any other person except your advisors and representatives in connection with the matters set forth herein.
This opinion shall be governed by and construed in accordance with the laws of Switzerland. We confirm our understanding that all disputes arising out of or in connection with this opinion shall be subject to the exclusive jurisdiction of the courts of the Canton of Zurich, Switzerland, venue being Zurich 1.
Sincerely yours
Homburger AG
Exhibit 10.3
AMENDMENT No. 3
Whereas, Addex Pharma SA (“Addex”) and Indivior UK Limited (Co. No. 7183451) (“Indivior”) (each a “Party” and collectively the “Parties”) entered into an agreement to perform research on GABA B PAM on January 2, 2018 (hereinafter, Agreement), an amendment dated October 30, 2020 (“Amendment 1”), and an amendment with an effective date of May 1, 2021 (“Amendment 2”); and
Whereas, Addex is conducting a funded research activity based on an agreed Research Plan over the period May 1, 2018 to July 31, 2022 and Indivior has committed $12.4 million in research funding over this period; and
Whereas, on completion of the Research Term, no Development Compounds have been identified but the Parties desire to continue the research with a view to identifying Development Compounds; and
Whereas, the Research Term, as defined in the Agreement, expires on July 31, 2022 pursuant to the terms of Amendment 2; and
Now Therefore, in consideration of the premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged Addex and Indivior hereby enter into this Amendment No. 3 (this “Amendment”) and agree as follows:
1. | Definitions. The definitions from the Agreement of January 2, 2018, Amendment 1 dated October 30, 2020 and Amendment 2 effective May 1, 2021 between Addex and Indivior shall be used in this Amendment and are incorporated herein by reference. |
2. | Amendment Effective Date. The effective date of this Amendment shall be August 1, 2022 (“Amendment Effective Date”). The Parties agree and acknowledge that this Agreement is executed as of the date of last signature below (the “Execution Date”) but shall be effective and binding on the Parties as of the Amendment Effective Date. |
3. | Initial Research Term Extension. With reference to Section 3.3 of the Agreement, subject to the provisions of this Amendment, the Parties agree to extend the Research Term until March 31, 2023. Accordingly, Section 1.72 is hereby deleted and replaced with the following: |
a. | “Research Term” means the period commencing on May 1, 2018 and expiring on March 31, 2023 unless the Parties agree to extend the Research Term pursuant to Section 3.3. |
4. | Contribution to Research Costs. The Parties agreed to extend the Research Term in previous amendments and agreed upon additional obligations of the Parties in relation to that additional research in Article 3 of Amendment 1 and Article 5 of the Amendment 2. Article 3 of Amendment 1 is hereby incorporated into the Agreement as Section 3.11. Article 5 of Amendment 2 is hereby incorporated into the Agreement as Section 3.12. The following is hereby incorporated into the Agreement as Section 3.13: |
a. | As a contribution to the costs of the research being conducted by Addex as detailed in the Research Plan in Appendix 1a & 1b, Indivior shall reimburse Addex the sum of up to eight hundred and fifty thousand Swiss Francs (CHF 850,000) for additional research funding as detailed in Appendix 2c in monthly installments based on activities completed by Addex. The amount of the above contribution attributable to any Reserved Indication shall be capped at four hundred thousand Swiss Francs (CHF 400,000). The Parties acknowledge that some activities being paid by the contribution have already been completed. Any additional activities from the date of the Amendment Effective Date for Reserved Indications shall only be for activities attributable to the Reserved Indications set forth in Section 1.73(h). The provisions of Section 6.9 of the Agreement shall apply to such payment. Addex shall provide an invoice for the payment due. Indivior shall support some activities through direct payments to third parties from a separate budget. For the sake of clarity, the Parties agree that any Know-How or other intellectual property created by any Third Party with whom Indivior contracts or makes payments for the purposes of the Research Plan shall be Joint Improvements regardless of which Party contributed to such Know-How or intellectual property and any Patent Rights filed in respect of such Joint Improvements shall be Joint Patent Rights regardless of inventorship. |
b. | On or before February 28, 2023, Addex shall deliver to Indivior a report that sets out all of their completed work to date on the compounds in the course of undertaking the Research Plan up to January 31, 2023 and identifying those which Addex believes are suitable for further development. |
c. | In the event that the costs of undertaking the Research Plan in Appendix 1b, exceed eight hundred and fifty thousand Swiss Francs (CHF 850,000), the Parties shall discuss the funding of that part of the Research Plan that exceeds such cost and Addex shall not be in breach of the Agreement if it elects not to undertake any part of the Research Plan that would result in the costs incurred by it in the Research Plan exceeding eight hundred and fifty thousand Swiss Francs CHF 850,000. |
d. | In the event that Indivior does not select any Licensed Compounds on or before March 31, 2023 the Agreement shall terminate in its entirety on March 31, 2023 and the provisions of Section 10.2 of the Agreement shall not apply. |
5. | Amendment of Definition of Reserved Indications. As of the Effective Date of this Amendment, the definition of Reserved Indications in Section 1.73 of the Agreement shall be deleted in its entirety and replaced by the following: |
1.73 “Reserved Indications” means the following Indications:
(a) Polyneuropathies and other disorders of the peripheral nervous system (G60 to G64) including but not limited to Charcot Marie Tooth (G60);
(b) Cerebral palsy and other paralytic syndromes (G80 to G83) including but not limited to cerebral palsy (G80);
(c) Nerve, nerve root and plexus disorders (G50 to G59) including but not limited to disorders of trigeminal nerve (G50);
(d) Neuromuscular dysfunction of bladder and other disorders of bladder (N31 to N32);
(e) Disorders of psychological development (F80-89) including but not limited to pervasive developmental disorders (F84) such as Rett’s syndrome (F84.2);
(f) Episodic & paroxysmal disorders (G40-47) including but not limited to Epilepsy (G40);
(g) Soft tissue disorders (M60-M79) including but not limited to Neuralgia and neuritis, unspecified (M79.2); and
(h) Pain, not elsewhere classified (G89) including but not limited to Neoplasm related pain, acute & chronic (G89.3).
(i) Cough (R05) and other abnormalities of breathing (R06) including but not limited to hiccough (R06.6)
(j) Idiopathic interstitial pulmonary diseases (J84) including but not limited to idiopathic pulmonary fibrosis (J84.112).
(k) Pruritus (L29)
(l) Gastro-oesophageal reflux disease (K21)
6. | Remainder of Agreement. The provisions of Section 14 of the Agreement shall apply to this Amendment and, save as specifically amended hereby, the Agreement of January 2, 2018 as amended on October 30, 2020 and May 1, 2021 will remain in full force and effect. |
IN WITNESS WHEREOF, ADDEX and Indivior have caused this instrument to be executed in duplicate by their respective duly authorized officers.
Indivior UK Limited. | ||
Date: | 31 July 2022 | |
By: | /s/ Gilles Picard | |
Title: Authorized Signatory |
Addex Pharma SA | ||
Date: | 31 July 2022 | |
By: | /s/ Tim Dyer | |
Title: Chief Executive Officer |
Exhibit 10.7
SALE AGENCY AGREEMENT
Between
ADDEX THERAPEUTICS
And
Kepler CHEUVREUX
Kepler Cheuvreux Siège social : 112 avenue Kléber 75116 Paris France |
http://www.keplercheuvreux.com/ | Tél : +33 1 53 65 35 00 | Société anonyme à Directoire et Conseil de surveillance au capital de 56.371.350 € RCS Paris B 413 064 841, APE 652 E Identification TVA FR 38413064841 Entreprise d’investissement régie par la loi n° 96-597 du 02.07.96 |
AGREEMENT
THIS SALE AGENCY AGREEMENT (the “Agreement”) IS MADE BY AND BETWEEN:
ADDEX THERAPEUTICS SA, a company incorporated under the laws of Switzerland, registered with the Trade and Companies Registry of the Canton of Geneva under no. CHE-113.514.094, whose registered office is at Chemin des Aulx 12, 1228 Plan-les-Ouates, Switzerland, represented by Tim Dyer, who is duly authorised to act on behalf of the above-mentioned company;
(hereinafter referred to as the “Client”),
AND:
KEPLER CHEUVREUX, a French Société Anonyme à Directoire et Conseil de Surveillance, registered on the Paris Trade and Companies Registry under number 413 064 841, whose registered office is located at 112, avenue Kléber, 75116 Paris, France, represented by Julia Aliche and Grégoire Varenne, duly empowered,
(hereinafter referred to as “Kepler Cheuvreux”),
Kepler Cheuvreux and the Client are hereinafter collectively called the "Parties", individually a “Party”.
WHEREAS:
1. The shares of the Client are admitted for trading on SIX Swiss Exchange (the “Exchange”) with the trading code ISIN CH0029850754 (the "Shares").
2. The Client has decided to entrust Kepler Cheuvreux with the sale of the Shares under the conditions determined by the Agreement and the General Terms and Conditions of Business which are available at the following address:
https://www.keplercheuvreux.com/app/uploads/2022/03/Terms-of-business-Kepler-Cheuvreux-01.02.2022.pdf (the "General Terms"). In the event of any contradictions between the General Terms and the Agreement, the Agreement shall prevail.
Kepler Cheuvreux Siège social : 112 avenue Kléber 75116 Paris France |
http://www.keplercheuvreux.com/ | Tél : +33 1 53 65 35 00 | Société anonyme à Directoire et Conseil de surveillance au capital de 56.371.350 € RCS Paris B 413 064 841, APE 652 E Identification TVA FR 38413064841 Entreprise d’investissement régie par la loi n° 96-597 du 02.07.96 |
IT IS HEREBY AGREED THAT:
Article 1 – PURPOSE OF THE AGREEMENT
1.1 | The Client entrusts Kepler Cheuvreux to sell a number of 10,000,000 Shares on its behalf and in accordance with the terms of Article 2 below. |
1.2 | Kepler Cheuvreux undertakes to sell the Shares in accordance with all applicable regulations, including Regulation (EU) n°596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (“MAR”). |
Article 2 – TERMS OF THE SALE OF THE SHARES
2.1 | Sale in the Exchange: |
Kepler Cheuvreux will make its best effort to sell the Shares in the Exchange.
2.2 | Kepler Cheuvreux will make its best efforts to proceed to the sale of the Shares by block trades outside the central order book of the Exchange. |
2.3 | The Shares shall be sold at a minimum price of 0.30 Swiss francs (“Minimum Price”). |
2.4 | The Minimum Price may be modified by phone by the Client, at any time, except during blackout period and shall be effective upon receipt by the Client of a confirmation by email from Kepler Cheuvreux. In addition, no sale will be allowed if the sale price is below the previous session’s closing price. |
2.5 | Kepler Cheuvreux will prepare a trade confirmation which sets out each individual purchase implemented under this Agreement ("Trade Confirmation") and will send it by e-mail to the Client on each day on which sales of Shares under this Agreement are executed. Each Trade Confirmation will indicate the corresponding settlement-delivery date (" Settlement-Delivery Date"). |
2.6 | The proceeds of the Shares’ sales shall be credited to account of the Client against delivery by the Client on the settlement date of the respective Shares (plus any applicable tax). |
Article 3 – INDEPENDENCE OF KEPLER CHEUVREUX
Within the framework of the mandate granted by the Client, Kepler Cheuvreux acts in full independence and in accordance with the terms determined in Article 2 above at the date of the signing of the Agreement.
Crédit Agricole Cheuvreux S.A.
9, quai du Président Paul Doumer – 92400 Courbevoie - France
Siren 788 108 223 RCS Nanterre - SA au capital de 39.239.816 EUR
Article 4 – EXCHANGE OF INFORMATION
4.1 | Within the framework of exchanges of information which may arise from the implementation of the Agreement, the Client shall not disclose to Kepler Cheuvreux any information likely to be qualified as inside information within the meaning of the applicable regulation according to the article 7 par. 1 to 4 of MAR. |
4.2 | If information of this nature is made known to Kepler Cheuvreux, the latter shall take all steps necessary to ensure that this information is not transmitted or used for its own account or on behalf of third parties, either directly or via another party. |
Article 5 – REMUNERATION OF KEPLER CHEUVREUX
5.1 Brokerage fee:
Kepler Cheuvreux shall receive a brokerage fee (excluding VAT and any securities transactions tax) equal to 0.75% of the gross proceeds from the sale of the Shares.
It is the Client’s sole responsibility to determine if transfer stamp duties apply. The Client shall pay any transfer stamp duties directly to the Swiss fiscal authorities if and when applicable.
5.2 Success fee:
In addition, if at the end of the mandate, the average gross selling price of the Shares is above the volume weighted average price (“VWAP”) of the Shares over the duration of the Agreement, Kepler Cheuvreux will be entitled to a success fee equal to:
0.15 x number of Shares sold x (average selling price per Share – VWAP)
Article 6 – DURATION
The Agreement shall come into force as of its date of signature until June 21, 2023 unless terminated earlier by either party.
Article 7 – WITHDRAWAL ANDTERMINATION
7.1 Each Party can at any time, without penalty, and without being required to provide a reason, therefore, terminate the Agreement, by notifying the other Party by letter, fax or email. Termination will take effect upon receipt of the above-mentioned notification.
7.2. Termination by Kepler Cheuvreux will take effect five Exchange trading days after the date on which the notification is sent to the Client.
7.3. The Client shall be entitled to suspend the Agreement at any time, except during blackout periods.
Article 8 – EXCLUSIVITY
The Agreement is granted exclusively to Kepler Cheuvreux. The Client is prohibited from appointing any other intermediary with a view to the sale of the Shares.
Crédit Agricole Cheuvreux S.A.
9, quai du Président Paul Doumer – 92400 Courbevoie - France
Siren 788 108 223 RCS Nanterre - SA au capital de 39.239.816 EUR
Article 9 – REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS
9.1 | The Client hereby represents that it has full knowledge of the regulations in effect concerning the use of inside information and the sanctions applicable in the event of non-compliance with the said regulations. |
9.2 | Moreover, the Client hereby represents that it does not possess, at the date of signature of the Agreement, inside information, within the meaning of the applicable regulations. |
9.3 | The Client hereby represents that it is the full owner of the Shares, that the latter are not pledged as collateral or security and are free of all liens, and more generally, any rights, restrictions or claims to the benefit of third parties, resulting from legal, regulatory or contractual obligations. |
9.4 | The Client hereby represents and warrants that it has not carried out, and will not carry out, for the duration of the Agreement, an offer of shares of the Company in any manner whatsoever outside the framework of the Agreement, and that it has not engaged in and will not engage in, for the duration of the Agreement, directly or indirectly, any stabilisation or manipulation of the price of the shares of the Company or in any other action intended to facilitate their sale in any manner whatsoever outside the framework of the Agreement. |
9.6 | Each Party severally represents that: (a) it has the capacity, power and authority to enter into this Agreement; (b) this Agreement has been duly authorized and executed by its competent authority and constitutes valid and legally binding obligations; (c) the making of this Agreement and the compliance with the terms hereof will not result in violation of the its constitutive documents or any provision contained in any law or regulation applicable to it; and (d) it will maintain all necessary consents and authorizations for the sale of Sell Shares contemplated by this Agreement. |
9.7 | The Client hereby represents that there is no lawsuit or legal or arbitration procedure, or any administrative or other measure pending that may result in the deterioration of its financial position or that may affect the validity or execution of the present agreement. |
9.8 | The Client undertakes to make known to Kepler Cheuvreux any event likely to affect the latter's capacity to execute its delivery obligations within the framework of the Agreement. |
Article 10 – LIMITATION OF LIABILITY AND INDEMNIFICATION
Kepler Cheuvreux does not guarantee the realization of the sale and does not undertake to buy the Shares for its own account. It is hereby agreed that Kepler Cheuvreux's obligation is limited to best efforts.
Neither Kepler Cheuvreux nor its parent companies, subsidiaries and affiliates, directors and officers (hereafter referred to collectively as the "Group") shall be liable to the Client, for any claim, loss, damage, liability, cost and/or expense (“Losses”) suffered by the Client or any such other person arising out of or related to the Agreement hereunder except for the Client Losses finally determined by a court and arising directly from any act or omission by Kepler Cheuvreux that constitutes gross negligence, wilful misconduct or fraud.
The Client irrevocably undertakes to indemnify, hold harmless and defend the Group, from and against any and all actions, claims or all damages, charges or disbursements of whatever nature, which may be made and/or suffered by all members of the Group in respect of, or arising out of any acts or omissions in the performance of this Agreement.
The provisions of this article shall remain in force beyond the termination or the expiration of the Agreement.
Crédit Agricole Cheuvreux S.A.
9, quai du Président Paul Doumer – 92400 Courbevoie - France
Siren 788 108 223 RCS Nanterre - SA au capital de 39.239.816 EUR
Article 11 – NOTICES
All notification made to the following addresses shall be valid:
- For KEPLER CHEUVREUX:
Cyril Gérard – Corporate Brokerage
Kepler Cheuvreux
112 Avenue Kleber
75116 Paris
Phone : +33 1 70 81 58 08
Email : cgerard@keplercheuvreux.com
- For the Client:
ADDEX THERAPEUTICS
Chemin des Aulx 12
1228 Plan-les-Ouates
Switzerland
Phone: +41228841555
Email: tim.dyer@addexpharma.com
Article 12 - PROTECTION OF PERSONAL DATA
The Parties undertake to comply with the legislation in force applicable to the processing of personal data and in particular with European Regulation 2016/679 of 27 April 2016 on the protection of individuals with regard to the processing of personal data and on the free movement of such data.
Article 13 – APPLICABLE LAW AND JURISDICTION
This Agreement and any non-contractual obligations arising under or in connection with this Agreement will be subject to and governed by French law. The French courts shall have jurisdiction to settle any dispute arising under or in connection with this Agreement.
Article 14 - ELECTRONIC SIGNATURE
This Agreement may be duly signed electronically and/or in duplicate in hard copy, either of which shall be sufficient for all purposes as evidence of the terms of this Agreement.
This Agreement is executed on June 21, 2022
Crédit Agricole Cheuvreux S.A.
9, quai du Président Paul Doumer – 92400 Courbevoie - France
Siren 788 108 223 RCS Nanterre - SA au capital de 39.239.816 EUR
For the Client
Name: | /s/ Tim Dyer | |
Title: CEO |
For KEPLER CHEUVREUX
/s/ Grégoire Varenne | /s/ Julia Aliche | |
General Group Manager | Managing Director, Group COO |
Crédit Agricole Cheuvreux S.A.
9, quai du Président Paul Doumer – 92400 Courbevoie - France
Siren 788 108 223 RCS Nanterre - SA au capital de 39.239.816 EUR
Exhibit 23.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form F-1 of Addex Therapeutics Ltd of our report dated April 24, 2020 relating to the financial statements, which appears in Addex Therapeutics Ltd's Annual Report on Form 20-F for the year ended December 31, 2021. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers SA
Geneva, Switzerland
August 19, 2022
1
Exhibit 23.4
Consent of Independent Registered Public Accounting Firm
Addex Therapeutics Ltd
Geneva, Switzerland
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 10, 2022, relating to the consolidated financial statements of Addex Therapeutics Ltd appearing in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO AG
Christoph Tschumi Nigel Le Masurier
Zurich, August 19, 2022
Exhibit 107
Calculation of Filing Fee Tables
Form F-1
(Form Type)
Addex Therapeutics Ltd.
(Exact Name of Registrant as Specified in Charter)
Table 1: Newly Registered and Carry Forward Securities
Security
Type | Security
Class Title | Fee Calculation or Carry Forward Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount
of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial effective date | Filing
Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |||||||||||||||||||||||||||
Newly Registered Securities | ||||||||||||||||||||||||||||||||||||||
Fees to Be Paid | Equity | Shares, nominal value CHF 1 per share (1) | 457 | (c) | 25,500,000 | $ | 1.37 | (2) | $ | 34,935,000.00 | 0.0000927 | 3,238.48 | N/A | N/A | N/A | $ | N/A | |||||||||||||||||||||
Fees Previously Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||||||||||||||||||||||||||
Carry Forward Securities | ||||||||||||||||||||||||||||||||||||||
Carry Forward Securities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||||||||||||||||||||||||||
Total Offering Amounts | 0.0000927 | $ | 3,238.48 | |||||||||||||||||||||||||||||||||||
Total Fees Previously Paid | $ | - | ||||||||||||||||||||||||||||||||||||
Total Fee Offsets | $ | - | ||||||||||||||||||||||||||||||||||||
Net Fee Due | $ | 3,238.48 |
(1) | These ordinary shares are represented by ADSs, each of which represents six ordinary shares of the registrant. ADSs issuable on deposit of the ordinary shares registered hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-235561). | |
(2) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based upon the average of the high and low prices of the registrant’s ADSs on the Nasdaq Capital Market on August 16, 2022, of $1.37. |
1SA<[BFZ(N/0I_(O5VQ9]TB"BZ(J1E
M3U[9+1:I
A]*M0?/'>-7?
MA^DSF_SA3_PY?>4^CEC^:L_8[T/I5J#YX[QJ[\/TF N6
MC:]=/:JPI\X8+3:U$RRK6VIWP6U*&(P,C$K;-Z^E;OI]FVZ]MJ:JZT.;S5Y+
MKK:0 2IIMY#1FXA)DD^$"H;>S$:8WW&7995EYNC)6U(>?ELLMU;AAV!#HQD+
M9&44IA:3A;RCF39 &B@PC>0>H)H$!-/E<<.!0 ,FU)N^ R)8
MS' 1LC;Y=SS,3^[O1U7HVW&6QBJS83;A$RM\RV0MREAV"X<*AD"Y!D)-SCV[
MK^B[WR"BZ@D3MCJ,HF33,8.H,8!U /)CR;$Q>M4V^LH7GTK? 98[UJ;2E18K0*;-5(RK6\MP*0,Z530$(5F\64E2VQLO=1J"PZ2UE3:CO?G
M132+S(0PAHA7@+3X2G%H*/&G-.:, .*&0F9S2-I
M )&)P/<.V.-")&*=S$12J0A2$*0A2$*0B[;"_+JR_P"-EN?CAG715?JSG\A7
MVC%Y;O[08^61^$(]OW^C]_\ I;#_ "<#7SC_ /.;_P >_K$?4S_V_?\ "W]3
MC65Z<_\ )7'_ -[W_P#*2VZW-]6/Q+C\HC]&Y&BOK=?E+9\D]^D:CS$UZ]CP
MY"D(4A'(H:CQ'3NB(:^QP =>Y7(" Y'G2>;POX?9BE4A"D(4A"D(4A%VV%^75E_P ;+<_'#.NBJ_5G/Y"OM&+R
MW?V@Q\LC\(1[?O\ 1^__ $MA_DX&OG'_ . U(]S[[22
MD*\7N2 \$2.. QX=@E859?Q2D(4A%0Z?K_ *E53XP[H@/XC$T9._)#$'\3
ME?W4A49;_P!8JOE(F;E^J4WR<0M4E$-"D(4A"D(4A"D(4A"D(4A"D(G)+O?I7.PMAYJL>IJ=4D
Q;
M5H;8+.+ANW\SWLGEB?L.3R%<]HWG?^*8QA.P&%8JSI86;Z2R/;@14O